REGISTER BY FRIDAY, APRIL 26 TO SAVE $600!

June 25-27, 2019 | Boston, MA

www.cell-engager-summit.com

Cell Engager Summit

Clinically Advancing the Next Generation of Safe & Effective Multi-Specific Immune Cell Engaging Antibody Therapies for Liquid & Solid Tumor Indications

Expert Speakers Include:

Omid Vafa
CBO
TeneoBio

Pavel Pisa
CMO
Crescendo Biologics

Holger Wesche
CSO
Harpoon Therapeutics

Michael Schmidt
VP of Antibody Discovery & Engineering
Compass Therapeutics

Cris Kamperschroer
Senior Principal Scientist
Pfizer

Chad May
SVP of Research & Development
Maverick Therapeutics

Industry Partner: ELSTAR THERAPEUTICS

Tel: +1 617 455 4188 **Mail:** info@hansonwade.com Cell Immunotherapy

hansonwade

WELCOME TO THE CELL ENGAGER SUMMIT

Minimize Toxicity to Create Safer Cell Engaging Drugs

The clinical proof of concept and potential of cell engager therapies has led to **investments and collaborations exploding in the field**, yet there are still numerous challenges that need to be overcome in order to fulfil their Therapeutic potential.

The Cell Engager Summit is the only meeting focused on translating and developing multi-specific cell engaging therapies in liquid and solid tumor indications. Accelerate target selection considerations and developments into the clinic whilst discovering how to **minimize cytokine release syndrome** to reduce safety concerns.

Bringing together the leaders from industry with solution and service providers, you will learn how to ensure **maximum efficacy** whilst **minimizing toxicity** to ease **patient dosing**. Discover the potential of cell engagers in **combination therapies** as we examine their **mechanisms of action** to be able to develop the best possible drugs.

Join us and leading experts from **Pfizer, Amgen, Compass Therapeutics, Harpoon Therapeutics, Regeneron** and **AbbVie** as they share their approaches to overcoming key challenges to accelerate the production of safe and effective cell engager drugs through **calculated target selection** for use in solid tumor indications.

Hear what previous attendees have to say

"The meeting was excellent. Fantastic presentations on the basic science as well as clinical experience"

"Very well organized meeting with top researchers in this field: great overview of a dynamic subject area"

"Very interesting presentations with an agenda and topics being current. The conference has been well organized and perfectly timed"

Your Checklist to Advancing Cell Engager Therapies

Minimize Toxicity of Cell Engagers to Ensure Patient Safety - Discover the key toxicities common with cell engagers and explore strategies to detect and minimize potential toxicities with **Cris Kamperschroer** of **Pfizer**



Develop Strategies to Ensure Manufacturing Scalability - Explore format and binding valency in developing manufacturable immune-redirecting bispecifics with **David Poon** of **Zymeworks**

Assess the Limitations of Cell Engagers in Solid Tumor Indications - Discover how to design platforms to reduce toxicity by restricting T cell engagement to within the tumor microenvironment with **Chad May** of **Maverick Therapeutics**



Analyze Target Selection to Maximize Efficacy Whilst Minimizing Toxicity - Analyze differences in the challenges of targets space, tumor microenvironment and drug exposures for target selection considerations and platform design with **Holger Wesche** of **Harpoon Therapeutics**

Focus on Dosing Regimens and the Therapeutic Window to Develop Easily Administered Drugs - Highlight ways to engineer half-life extension of cell engager drugs to ease drug administration and examining dosing strategies to mitigate the effects of cytokine release syndrome

YOUR EXPERT SPEAKERS

Jijie Gu
Director, Head of Target Validation & Discovery & Immunology Research Lead
AbbVie

Gabriela Hernandez-Hoyos
Leader of Immunobiology Group
Aptevo Therapeutics

Julie Bailis
Principal Scientist
Amgen

Anthony Stein
Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope

Michael Schmidt
VP of Antibody Discovery & Engineering
Compass Therapeutics

Pavel Pisa
CMO
Crescendo Biologics

Steve Arkinstall
President & CEO
Elstar Therapeutics

Charles Sentman
Director of Center for Synthetic Immunity & Professor
Geisel School of Medicine at Dartmouth

Holger Wesche
CSO
Harpoon Therapeutics

Rick Austin
Senior Director of Biology
Harpoon Therapeutics

Joseph Dukes
Director, Program Leader & Head of Preclinical Biology
Immunocore

Ross La Motte-Mohs
Cell Biology, Immunology & Research Scientist
MacroGenics

Chad May
SVP of Research & Development
Maverick Therapeutics

Cris Kamperschroer
Senior Principal Scientist
Pfizer

Jessica Kirshner
Senior Director of Oncology
Regeneron Pharmaceuticals

Omid Vafa
CBO
TeneoBio

Seung Chu
Associate Director - Cell Biology
Xencor

David Poon
VP of Business Development & Alliance Management
Zymeworks

PRE-CONFERENCE WORKSHOP DAY TUESDAY, JUNE 25 2019

Workshop A

Developing Efficacious T Cell Engager Modalities for Targeting Solid Tumors

9:00am – 12:00pm

T cell engagers targeting solid tumors need to achieve an efficacious exposure at a distant tumor site, while at the same time avoiding toxicities caused by high exposures in normal tissues. In contrast, in hematologic malignancies, T cell engagers generally target tumors cells that are in or close to the circulatory system, making it easier to achieve a tolerated therapeutic dose.

Attend this workshop to:

- Discuss design consideration for the development of T cell engagers for solid tumors
- Focus on target selection, tumor penetration, half-life extension and stability of the modality under physiological conditions

Workshop Leaders

Holger Wesche
CSO
Harpoon Therapeutics

Dr. Wesche joined Harpoon Therapeutics with 20 years of biotech experience focused on target validation, drug discovery and drug development as well as multi-site project management in the fields of oncology and inflammation. His previous role was as scientific director at Amgen where he was responsible for cross-functional organization and coordination of the next generation BiTE platform, the industry's leading T-cell engaging antibody platform. He also led several drug discovery projects through pre-clinical development. Dr. Wesche is co-author of numerous publications and several US patents. Dr. Wesche received his PhD, summa cum laude, in biochemistry and Immunology from the University of Hannover, Germany.

Rick Austin
Senior Director of Biology
Harpoon Therapeutics

Dr. Austin is the Senior Director of Biology Research at Harpoon Therapeutics, previously having worked at Amgen and Tularik. In his 18 years of biotech experience in the field of oncology, he has led small and large molecule programs focusing on target validation, drug discovery, and drug development. His work has produced multiple publication and patents. Dr. Austin received his PhD in Molecular Biology and Biophysics from Yale University and received postdoctoral training at the Massachusetts Institute of Technology.

Workshop B

Analyzing the Importance of Target Selection in Early Cell Engager Development

1:00pm – 4:00pm

The choice of target in the cell engager space is paramount. Careful analysis of target characteristics, including expression profile and accessibility can aid the decision making process to find targets which will have maximal efficacy without compromising safety. Attend this workshop to verify the importance of target selection in early development.

In this workshop we will:

- Hear case-by-case examples of the impact of target selection on the efficacy and safety of cell engager drugs
- Learn what characteristics of a target impact potential for success
- Explore how specific binding modes or molecule formats can impact potency and efficacy

Workshop Leader

Julie Bailis
Principal Scientist
Amgen

Julie Bailis, PhD, is a Principal Scientist in Oncology Research at Amgen. Julie's team is responsible for the discovery and development of novel oncology therapeutics, from target identification and validation through support for first in human clinical studies. Her research over the past six years has centered on bispecific T-cell engager antibody constructs for solid tumors. Julie was a Damon Runyon postdoctoral fellow at the Salk Institute for Biological Studies, where her work focused on the DNA damage response and mechanisms of genome instability in cancer. She obtained her PhD in Molecular and Cellular Biology from Yale University.

CONFERENCE DAY ONE
WEDNESDAY, JUNE 26 2019

8.45 Chair's Opening Remarks

Analyzing Target Selection to Maximize Efficacy Whilst Minimizing Toxicity

Holger Wesche
CSO
Harpoon Therapeutics

9.00 TriTACs – Development Challenges and Opportunities for Novel T Cell Engagers

- T cell engager background: work well in liquid tumors, limited success in solid tumors so far
- Analysis of differences: targets space, tumor microenvironment, drug exposures
- Considerations for target selection and platform design to address these challenges
- Description of the TriTAC platform
- End with an update on the lead program, HPN424, currently in the clinic for the treatment of prostate cancer

Michael Schmidt
VP of Antibody Discovery & Engineering
Compass Therapeutics

9.30 A Novel Class of NK-cell Engagers for Tumor Targeting

- Compass Tx has developed a NK-cell engager platform targeting various tumor antigens
- NK-cell engagers bind to tumor antigens on tumor cells and to NKp30 and CD16A (FcgRIIIA) on NK cells, specifically redirecting NK cells towards tumor cells expressing low level of tumor antigen

Joseph Dukes
Director, Program Leader & Head of Preclinical Biology
Immunocore

10.00 The ImmTACTM Platform: Progress and Clinical Insight from the Soluble TCR-based Bispecific Approach

- Introduce the ImmTAC platform and discuss the potential benefits of TCR-based targeting
- Present clinical data and learnings from trials with IMCgp100, the lead ImmTAC in pivotal/Ph3 trials
- Update on the pipeline with some preclinical data on ImmTAC reagents in early stage clinical trials

10.30 Morning Refreshments & Speed Networking

Pavel Pisa
CMO
Crescendo Biologics

11.30 Humabody® VH as T-cell Enhancing Therapeutics for Immuno Oncology

- Not all T cell bispecifics are equal
- Considerations for safer and more durable anti-cancer immune responses
- Humabody® VH Platform - Strengths and challenges of the Humabody® VH Platform
- PSMA-CD137 multispecific Humabody® - the frontrunner into the clinic

Developing Strategies to Ensure Scalability of Cell Engagers

David Poon
VP of Business Development & Alliance Management
Zymeworks

12.00 Exploring Formats and Binding Valency in Developing Manufacturable Immune-Redirecting Bispecifics

- Overview of the best-in-class Azymetric™ platform for generating bispecifics
- Highlighting engineering strategies to improve manufacturability
- Optimizing activity of immune-engaging bispecifics and correlations with formats and binding valency

12.30 Lunch & Networking

Jijie Gu
Director, Head of Target Validation & Discovery & Immunology Research Lead
AbbVie

1.30 The Promise of Next Generation T Cell Engagers for Cancer Treatment

- Bispecific T cell engagers are able to bring T cells proximity to cancer cells for tumor killing
- By bringing in additional immune modulatory specificity to address tumor immune-escaping mechanisms and to overcome immunosuppressive tumor microenvironment, next generation multi-specific T cell engagers may hold great promise to rival CAR-T therapies with several potential advantages

Ross La Motte-Mohs
Cell Biology, Immunology & Research Scientist
MacroGenics

2.00 Clinical and Translational Experience from a Phase I Clinical Study of Flotetuzumab, a CD123 x CD3 DART® Molecule, in Acute Myeloid Leukemia

- Flotetuzumab is designed to target T cells to kill CD123-expressing tumor cells present in acute myeloid leukemia (AML) and other hematologic malignancies
- In Phase I studies, flotetuzumab elicits anti-leukemic activity in relapse/refractory (R/R) AML patients with a dosing strategy optimized to potentially ameliorate cytokine release syndrome (CRS)
- Translational studies also demonstrate the emergence of an exhaustion T-cell phenotype in non-responders and support the rationale for combining flotetuzumab with checkpoint blockade (i.e.: anti-PD-1)

2.30 Afternoon Refreshments & Poster Session

3.00 Round Table Discussion

Analyzing Target Selection

- What is the impact of construct design on bioactivity, safety and efficacy?
- Does variation in affinity for antigens lead to a different outcome in preclinical studies?
- How does CD3 and/or tumor antigen binding affinity affect bioactivity, safety and efficacy?

Discussing Manufacturing Limitations

- What are the difficulties of manufacturing antibodies with bespoke designs?
- Addressing the importance of designing antigens that maintain efficacy when put into cell engager format
- Examining how simple and robust platforms affect manufacturability and the ultimate success of a cell engager

Comparing Cell Engagers with CAR Therapeutics

- Evaluating how the off-the-shelf nature of cell engagers can reduce manufacturing costs and treatments time to create a more available therapeutic
- Verifying how and why the small size of some cell engagers allows for better efficacy in solid tumor indications
- Comparing cell engagers with CAR-T and discussing possible combination therapies

4.30 Chair's Closing Remarks

4.45 End of Day 1

"The meeting was excellent. Fantastic presentations on the basic science as well as clinical experience"

Previous Hanson Wade Meeting Attendee

CONFERENCE DAY TWO
THURSDAY, JUNE 27 2019

8.25 Chair's Opening Remarks

Exploring Means to Minimize Toxicity of Cell Engagers to Ensure Patient Safety

Cris Kamperschroer
Senior Principal Scientist
Pfizer

8.30 Reducing Key Toxicities with T Cell Engaging Bispecifics

- What are the key toxicities that are common with T cell engagers?
- Exploring strategies Pfizer has used to detect and minimize potential toxicities, with a focus on solid tumor indications
- Examining how to reduce CRS with different approaches, including pharmacological blockade of cytokines

Steve Arkinstall
President & CEO
Elstar Therapeutics

9.00 A New Concept for Cancer Immunotherapies with Robust Efficacy and Minimal Toxicity

- Elstar's molecules are built to target tumors through binding simultaneously two cell surface antigens allowing precision delivery of one or more of our immune engager modules.
- Our non-CD3 T cell engager drives expansion and activation of a discrete T cell population without generating cytokines responsible for CRS
- We also have developed a new generation of immunocytokine with radically different pharmacology allowing both enhanced tumor targeting and reduced systemic toxicity

Omid Vafa
CBO
TeneoBio

9.30 A Novel Multispecific T Cell Engager Platform for a Better Therapeutic Window

- TeneoBio's sequence-based discovery: Profiling the B-cell repertoire of human Ig transgenic rats for diverse leads against target antigens of interest
- Identifying and optimizing multi-specific leads for a novel CD3-based T-cell engager platform
- Mitigating safety risk with T-cell engagers that maximize target cancer cytotoxicity and minimize cytokine release
- Improving the therapeutic window of T-cell engagers for combination therapies

Anthony Stein
Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope

10.00 Prevention and Treatment of CRS with Bispecific Antibodies

- Prevention –Dose step, Medication
- Treatment – Steroids, Tocilizumab
- Grading System

10.30 Morning Refreshments & Networking

Seung Chu
Associate Director - Cell Biology
Xencor

11.00 Maximizing Therapeutic Potential by Affinity and Avidity Engineering

- Antigen affinity optimization for increased exposure and reduced toxicity
- Multi-valent antibody scaffold for avidity-mediated tumor selectivity

Assessing the Limitations of Cell Engagers in Solid Tumor Indications

Chad May
SVP of Research & Development
Maverick Therapeutics

11.30 COBRA™: A Novel Conditionally Active T-cell Engager Platform

- Solid tumor directed T-cell engaging bispecifics are limited by target expression on normal tissues
- COBRA™ platform is designed to reduce toxicity by restricting T cell engagement to within the tumor microenvironment
- Review the pros and cons of solid tumor xenograft models to measure efficacy
- Demonstrate potent COBRA™ mediated tumor regressions

Julie Bailis
Principal Scientist
Amgen

12.00 Rational Combinations for Bispecific T-cell Engager (BiTE®) Immune Therapy in Solid Tumors

Gabriela Hernandez-Hoyos
Leader of Immunobiology Group
Aptevo Therapeutics

12.30 Utility of the ADAPTIR™ Platform to Engage and Modulate Immune Cells for the Treatment of Cancer and Autoimmune/Inflammatory Diseases

- Overview of the ADAPTIR™ platform and screening methodology to identify active, manufacturable bispecific proteins
- APVO436, an anti-CD3 T-cell engager with unique characteristics for the treatment of AML
- ALG.APV-527, an anti-41BB x 5T4 bispecific that engages T cells for the treatment of solid tumors

1.00 Lunch & Networking

Anthony Stein
Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope

Seung Chu
Associate Director - Cell Biology
Xencor

Cris Kamperschroer
Senior Principal Scientist
Pfizer

Julie Bailis
Principal Scientist
Amgen

2.00 Panel Discussion: Focusing on Dosing Regimens and the Therapeutic Window in order to Develop Easily Administered Drugs

- Exploring the potential ability of drugs with short serum half-lives allowing precise control of drug levels within the patient to enhance their potential safety
- Determining the exposure levels needed for cell engagers to be effective
- Understanding the importance of dose selection and escalation
- What preclinical information is actually useful?
- Do we really need to start at the MABEL dose or could we start higher for terminal indications?

3.00 Afternoon Refreshments

Discovering the Importance of Understanding Cell Engager Mechanisms

Jessica Kirshner
Senior Director of Oncology
Regeneron Pharmaceuticals

3.30 Testing Efficacy and Safety of Ovarian-Cancer Targeted Bispecific Antibodies in Mouse and Cynomolgus Monkey Models

- Development of unique immunocompetent murine models to simultaneously investigate effects of CD3-bispecifics on tumors and normal tissues
- Using iPET imaging to understand localization of bispecific antibodies in these unique murine models

Charles Sentman
Director of Center for Synthetic Immunity & Professor
Geisel School of Medicine at Dartmouth

4.00 Mechanisms of Bispecific T cell Engager Efficacy and Toxicity in Murine Tumor Models

- Efficacy and mechanisms of action against lymphoma
- Efficacy and mechanisms of action against metastatic melanoma
- Mechanisms associated with acute off-tumor toxicity

4.30 Chair's Closing Remarks

4.35 Close of Conference

WHY PARTNER

Speaking Opportunities
Position yourself as the thought leader in your space and educate the market

Panel Moderator
Curate and drive the conversation alongside leaders of the field

Roundtable Leader
Interact intimately with your market audience to understand their needs

Workshop Leader
Lead a focused and in-depth discussion with a targeted audience

Exclusive VIP Hosting
Build or cement relationships through informal channels

Exhibition Stand
Have your flag in the ground and showcase your technology to the onsite community of senior decision makers

Industry Partner

ELSTAR THERAPEUTICS

Elstar Therapeutics is fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating antibody-based, multi-functional therapeutics.
Armed with a unique approach to engaging multiple immune mechanisms, we enable patients to harness their own body to fight cancer.
Our Universal Targeted Immunotherapy (UniTI™) platform positions us to overcome barriers that have limited the full potential of other promising immunotherapeutic approaches.
"Our motivation...to be part of the cure for cancer"

www. elstartherapeutics.com

Attendance by Company Type*



Attendance by Geo*



*Expected

GET INVOLVED

Andreea Dogaru
Partnerships Director
Tel: +44 2038542902
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.cell-engager-summit.com

Tel: +1 617 455 4188

Email: register@hansonwade.com

Network with the experts and leaders of the Cell Engager community and take this opportunity to make collaborative partnerships for future clinical prospects.

Hear the novel clinical data from trials and apply the lessons learnt to future pipelines to ensure future efficacy.

Learn from the leaders in the space and join the communal discussion finding solutions to limiting manufacture and regulatory issues.

Team Discounts*

10% discount- 3 Delegates
15% discount- 4 Delegates
20% discount- 5 or More Delegates
Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.
Contact: register@hansonwade.com

SECURE YOUR PLACE

Industry Pricing	Register & Pay By Friday, April 26	Standard Prices
Conference + 2 Workshops	$3497 **(save $600)**	$3897 **(save $200)**
Conference + 1 Workshop	$2998 **(save $500)**	$3398 **(save $100)**
Conference Only	$2499 **(save $400)**	$2899
Workshop Only	$599	

40% discount for academics using code 'ACA'

VENUE

Revere Hotel Boston Common
200 Stuart Street, Boston
Massachusetts, 02116 USA

For further information or assistance, please visit www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 12849